CTRI/2018/05/013922尚未招募未知
Multinational, cross sectional, observational study to describe glycemic control and quality of life for type 1 diabetic adult patients - SAGE
Sanofi Synthelabo India Private Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1 Male or female.
- •2 Age greater than or equal to 26 years old.
- •3 Clinical diagnosis of presumed autoimmune T1DM treated by insulin.
- •4 Diagnosis of T1DM greater oe equal to 1 year.
- •5 Glycated hemoglobin value available within 30 days preceding the study visit or planned to be obtained in routine practice within 7 days after the study visit.
- •7 Signed written informed consent.
排除标准
- •1 Diabetes other than type 1 diabetes eg, type-2 diabetes, secondary diabetes mellitus pancreatic history, drug or chemical-induced diabetes, genetic defects in beta cell function or insulin action.
- •2 Patients unable to understand the nature and scope of the study, unable to read and write or unlikely to comply with the protocol, eg, inability and unwillingness to complete the PRO questionnaires.
- •3 Change from pump regimen to multiple insulin injections regimen, or switch from multiple dose injections to pump regimen within the last 3 months preceding study visit.
- •4 Treatment with oral antidiabetic drugs
- •thiazolidinedione, sulfonylurea, dipeptidyl peptidase 4 inhibitors at any time from the diagnosis of T1DM.
- •5 Treatment with any investigational drug within the last 3 months
研究者
相似试验
招募中
4 期
To understand the prevalence of Respiratory diseases in Asia.CTRI/2013/02/003386MSD Pharmaceuticals Pvt Ltd5,250
进行中（未招募）
1 期
Estudio multinacional, multicéntrico, randomizado, doble ciego, de grupos paralelos, controlado con placebo, para evaluar la seguridad, tolerabilidad y eficacia de la administración oral de laquinimod 0,6mg una vez al día en pacientes con esclerosis múltiple remitente recurrente (RRMS). - AllegroEsclerosis Múltiple Remitente Recurrente (RRMS)MedDRA version: 9.1Level: PTClassification code 10028245Term: Multiple sclerosisEUCTR2007-003226-19-ESTeva Pharmaceutical Industries Ltd1,000
进行中（未招募）
不适用
Estudio multinacional, multicéntrico, randomizado, de grupos paralelos realizado en pacientes con Esclerosis Múltiple Remitente Recurrente (RRMS) para evaluar la eficacia, seguridad y tolerabilidad de laquinimod frente a placebo con un diseño doble ciego y con una rama con Interferón ß-1a (Avonex®) como tratamiento de referencia con evaluador ciego - BRAVOEUCTR2007-005450-23-ESTeva Pharmaceutical Industries Ltd1,200
进行中（未招募）
1 期
Estudio multinacional, multicéntrico, randomizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia, tolerabilidad y seguridad de Talampanel en pacientes con Esclerosis Lateral Amiotrófica (ELA)A Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Tolerability and Safety of talampanel in Subjects with Amyotrophic Lateral Sclerosis (ALS)Esclerosis Lateral Amiotrófica (ELA).Amyotrophic lateral sclerosis (ALS).MedDRA version: 9.1Level: PTClassification code 10052653Term: Amyotrophic lateral sclerosis gene carrierEUCTR2008-002062-62-ESTeva Pharmaceutical Industries, Ltd
已完成
1 期
A multicentre, multinational prospective observational imaging biomarker study in early stage Huntington?s disease (HD) patients to assess imaging techniques and parameters able to support efficacy studies with SEN0014196 in HD patients during Phase II and III studiesISRCTN26193242Siena Biotech (Italy)60